Feng Yutao, Ma Fen, Wu Enjiang, Cheng Zewei, Wang Zhengtao, Yang Li, Zhang Jiwei
Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Pharmacol. 2022 Oct 31;13:922029. doi: 10.3389/fphar.2022.922029. eCollection 2022.
In the past decade, immunotherapy has been the most promising treatment for gastrointestinal tumors. But the low response rate and drug resistance remain major concerns. It is therefore imperative to develop adjuvant therapies to increase the effectiveness of immunotherapy and prevent drug resistance. Ginseng has been used in Traditional Chinese medicine as a natural immune booster for thousands of years. The active components of ginseng, ginsenosides, have played an essential role in tumor treatment for decades and are candidates for anti-tumor adjuvant therapy. They are hypothesized to cooperate with immunotherapy drugs to improve the curative effect and reduce tumor resistance and adverse reactions. This review summarizes the research into the use of ginsenosides in immunotherapy of gastrointestinal tumors and discusses potential future applications.
在过去十年中，免疫疗法一直是胃肠道肿瘤最有前景的治疗方法。但低反应率和耐药性仍然是主要问题。因此，开发辅助疗法以提高免疫疗法的有效性并预防耐药性势在必行。人参在传统中医中作为天然免疫增强剂已使用了数千年。人参的活性成分人参皂苷在肿瘤治疗中发挥了数十年的重要作用，是抗肿瘤辅助治疗的候选药物。据推测，它们可与免疫治疗药物协同作用，提高疗效，降低肿瘤耐药性和不良反应。本文综述了人参皂苷在胃肠道肿瘤免疫治疗中的应用研究，并探讨了其潜在的未来应用。
